The Practice of Hypoglycemic Therapy: Choosing the Optimal Drug from the Group of Dipeptidyl Peptidase 4 Inhibitors
Effective treatment of type 2 diabetes mellitus is an important task of modern medicine. Recently, the possibilities of hypoglycemic therapy have significantly expanded, due to the continuous development of diabetology, the deepening of ideas about the pathophysiology of the disease. In particular, the importance of the incretin system in glucose homeostasis and incretin-directed therapy is discussed. Drugs with incretin activity include dipeptidyl peptidase 4 inhibitors (iDPP-4). Several DPP-4 inhibitors have been registered in the Russian Federation: alogliptin, vildagliptin, hemigliptin, gozogliptin, linagliptin, saxagliptin, sitagliptin, evogliptin. The article presents the results of clinical studies of the efficacy and safety of iDPP-4. Special emphasis is placed on choosing the optimal drug from the iDPP-4 group. The introduction of a new Russian drug from the iDPP-4 group to the pharmaceutical market will provide patients with type 2 diabetes with modern, effective and affordable treatment.